|
[1]
|
Liu, C., Lyu, H., Niu, P., Tan, J. and Ma, Y. (2020) Association between Diabetic Neuropathy and Osteoporosis in Pa-tients: A Systematic Review and Meta-Analysis. Archives of Osteoporosis, 15, Article No. 125. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Lotfy, M., Adeghate, J., Kalasz, H., Singh, J. and Adeghate, E. (2017) Chronic Complications of Diabetes Mellitus: A Mini Review. Current Diabetes Reviews, 13, 3-10. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Kolluru, G.K., Bir, S.C. and Kevil, C.G. (2012) En-dothelial Dysfunction and Diabetes: Effects on Angiogenesis, Vascular Remodeling, and Wound Healing. International Journal of Vascular Medicine, 2012, Article ID: 918267. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Hayyan, M., Hashim, M.A. and Al Nashef, I.M. (2016) Superoxide Ion: Generation and Chemical Implications. Chemical Reviews, 116, 3029-3085. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Saito, M., Fujii, K., Soshi, S., et al. (2006) Reductions in Degree of Mineralization and Enzymatic Collagen Cross- Links and Increases in Glycation-Induced Pentosidine in the Femoral Neck Cortex in Cases of Femoral Neck Fracture. Osteoporosis International, 17, 986-995. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Li, G., Xu, J. and Li, Z. (2012) Receptor for Advanced Glycation End Products Inhibits Proliferation in Osteoblast through Suppression of Wnt, PI3K and ERK Signaling. Biochemical and Biophysical Research Communications, 423, 684-689. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Ding, K.H., Wang, Z.Z., Hamrick, M.W., et al. (2006) Disordered Osteoclast Formation in RAGE Deficient Mouse Establishes an Essential Role for RAGE in Diabetes Related Bone Loss. Biochemical and Biophysical Research Communications, 340, 1091-1097. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Hein, G.E. (2006) Glycation Endproducts in Osteoporosis—Is There a Pathophysiologic Importance? Clinica Chimica Acta, 371, 32-36. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Patel, R., Shervington, A., Pariente, J.A., et al. (2006) Mechanism of Exocrine Pancreatic Insufficiency in Streptozotocin-Induced Yype 1 Diabetes Mellitus. Annals of the New York Academy of Sciences, 1084, 71-88. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Chen, H. and Li, J. (2018) Wang Q Associations between Bone-Alkaline Phosphatase and Bone Mineral Density in Adults with and without Diabetes. Medicine, 97, Article ID: e0432. [Google Scholar] [CrossRef]
|
|
[11]
|
Ala, M., Jafari, R.M. and Dehpour, A.R. (2020) Di-abetes Mellitus and Osteoporosis Correlation: Challenges and Hopes. Current Diabetes Reviews, 16, 984-1001. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Adler, R. A., et al. (2013) Glucocorticoid-Induced Osteoporosis. In: Marcus, R. et al., Eds., Osteoporosis, Academic Press, Cambridge, MA, 1191-1223. [Google Scholar] [CrossRef]
|
|
[13]
|
Darjani, A., Nickhah, N., Hedayati Emami, M.H., et al. (2017) Assessment of the Prevalence and Risk Factors Associated with GlucocorticoidInduced Diabetes Mellitus in Pemphigus Vulgaris Patients. Acta Medica Iranica, 55, 375-380.
|
|
[14]
|
Weinstein, R.S., Jilka, R.L., Parfitt, A.M. and Manolagas, S.C. (1998) Inhibition of Osteoblastogenesis and Promotion of Apoptosis of Osteoblasts and Osteocytes Byglucocorticoids. Potential Mechanisms of Their Deleterious Effects on Bone. Journal of Clinical Investigation, 102, 274-282. [Google Scholar] [CrossRef]
|
|
[15]
|
Almeida, M., Han, L., Ambrogini, E., Weinstein, R.S. and Mano-lagas, S.C. (2011) Glucocorticoids and Tumor Necrosis Factor α Increase Oxidative Stress and Suppress Wnt Protein Signaling in Osteoblasts. Journal of Biological Chemistry, 286, 44326-44335. [Google Scholar] [CrossRef]
|
|
[16]
|
Jagpal, A., De, S.D., Singh, S.A. and Kirk, A. (2018) Is Tacrolimus More Likely to Induce Diabetes Mellitus Than Ciclosporin in Heart Transplant Patients? Vessel Plus, 2, Article No. 24. [Google Scholar] [CrossRef]
|
|
[17]
|
Velleca, A., Kittleson, M., Patel, J., Rafiei, M., Osborne, A., Ngan, A., et al. (2013) Tacrolimus-Versus Cyclosporine- Induced Diabetes Leads to More Diabetic Complications after Heart Transplantation. The Journal of Heart and Lung Transplantation, 32, S202. [Google Scholar] [CrossRef]
|
|
[18]
|
Baran, D., Ashkar, J., Galin, I., Sandler, D., Segura, L., Court-ney, M., et al. (2002) Tacrolimus and New Onset Diabetes Mellitus: The Effect of Steroid Weaning. Transplantation Proceedings, 34, 1711-1712. [Google Scholar] [CrossRef]
|
|
[19]
|
Li, Z., Sun, F., Zhang, Y., et al. (2015) Tacrolimus Induces Insulin Resistance and Increases the Glucose Absorption in the Jejunum: A Potential Mechanism of the Diabetogenic Ef-fects. PLoS ONE, 10, Article ID: e0143405. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Rodríguez-Rodríguez, A.E., Triñanes, J., Porrini, E., et al. (2015) Glucose Homeostasis Changes and Pancreatic β-Cell Proliferation after Switching to Cyclosporin in Tacroli-mus-Induced Diabetes Mellitus. Nefrologia, 35, 264-272. [English Edition]. [Google Scholar] [CrossRef]
|
|
[21]
|
Triñanes, J., Rodriguez-Rodriguez, A.E., Brito-Casillas, Y., et al. (2017) Deciphering Tacrolimus-Induced Toxicity in Pancreatic β Cells. American Journal of Transplantation, 17, 2829-2840. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Sheu, A. and Diamond, T. (2016) Secondary Osteoporosis. Australian Prescriber, 39, 85-87. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Spolidorio, L.C., Nassar, P.O., Nassar, C.A., Spolidorio, D.M. and Muscará, M.N. (2007) Conversion of Immunosuppressive Monotherapy from Cyclosporin A to Tacrolimus Re-verses Bone Loss in Rats. Calcified Tissue International, 81, 114-123. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Ponticelli, C., Aroldi, A., Goffin, E., Devendra, D. and Wilkin, T. (2001) Osteoporosis after Organ Transplantation. Lancet, 357, 1623. [Google Scholar] [CrossRef]
|
|
[25]
|
Martin-Fernandez, M., Rubert, M., Montero, M. and De La Piedra, C. (2017) Effects of Cyclosporine, Tacrolimus, and Rapamycin on Osteoblasts Transplantation Proceedings, 49, 2219-2224. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Smallwood, G., Burns, D., Fasola, C., Steiber, A. and Heffron, T. (2005) Relationship between Immunosuppression and Osteoporosis in an Outpatient Liver Transplant Clinic. Transplantation Proceedings, 37, 1910-1911. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Goldner, M.G., Zarowitz, H. and Akgun, S. (1960) Hy-perglycemia and Glycosuria Due to Thiazide Derivatives Administered in Diabetes Mellitus. New England Journal of Medicine, 262, 403-405. [Google Scholar] [CrossRef]
|
|
[28]
|
Scheen, A.J. (2018) Type 2 Diabetes and Thiazide Diuretics. Current Diabetes Reports, 18, Article No. 6. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Zillich, A.J., Garg, J., Basu, S., Bakris, G.L. and Carter, B.L. (2006) Thiazide Diuretics, Potassium, and the Development of Diabetes: A Quantitative Review. Hypertension, 48, 219-224. [Google Scholar] [CrossRef]
|
|
[30]
|
Shafi, T., Appel, L.J., Miller III, E.R., Klag, M.J. and Parekh, R.S. (2008) Changes in Serum Potassium Mediate Thiazide-Induced Diabetes. Hypertension, 52, 1022-1029. [Google Scholar] [CrossRef]
|
|
[31]
|
Rapoport, M.I. and Hurd, H.F. (1964) Thia-zide-Induced Glucose Intolerance Treated with Potassium. Archives of Internal Medicine, 113, 405-408. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Helderman, J.H., Elahi, D., Andersen, D.K., Raizes, G.S., Tobin, J.D., Shocken, D., et al. (1986) Prevention of the Glucose Intolerance of Thiazide Diuretics by Maintenance of Body-Potassium. In: Krück, F. and Schrey, A., Eds., Diuretika III, Springer, Berlin, Heidelberg, 98-109. [Google Scholar] [CrossRef]
|
|
[33]
|
Brown, M.J., Williams, B., Morant, S.V., et al. (2016) Effect of Amiloride, or Amiloride plus Hydrochlorothiazide, Versus Hydrochlorothiazide on Glucose Tolerance and Blood Pressure (PATHWAY-3): A Parallelgroup, Double-Blind Randomised Phase 4 Trial. The Lancet Diabetes & Endocri-nology, 4, 136-147. [Google Scholar] [CrossRef]
|
|
[34]
|
Transbøl, I., Christensen, M.S., Jensen, G.F., Christiansen, C. and McNair, P. (1982) Thiazide for the Postponement of Postmenopausal Bone Loss. Metabolism, 31, 383-386. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Cauley, J.A., Cummings, S.R., Seeley, D.G., et al. (1993) Ef-fects of Thiazide Diuretic Therapy on Bone Mass, Fractures, and Falls. Annals of Internal Medicine, 118, 666-673. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Xiao, X., Xu, Y. and Wu, Q. (2018) Thiazide Diuretic Usage and Risk of Fracture: A Meta-Analysis of Cohort Studies. Osteoporosis International, 29, 1515-1524. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Legroux-Gerot, I., Catanzariti, L., Marchandise, X., Duquesnoy, B. and Cortet, B. (2004) Bone Mineral Density Changes in Hypercalciuretic Osteo Porotic Men Treated with Thiazide Diuretics. Joint Bone Spine, 71, 51-55. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Kruse, C., Eiken, P. and Vestergaard, P. (2016) Continuous and Long-Term Treatment Is More Important Than Dosage for the Protective Effect of Thiazide Use on Bone Metabolism and Fracture Risk. Journal of Internal Medicine, 279, 110-122. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Cheng, L., Zhang, K. and Zhang, Z. (2018) Effectiveness of Thiazides on Serum and Urinary Calcium Levels and Bone Mineral Density in Patients with Osteoporosis: A Systematic Review and Meta-Analysis. Drug Design, Development and Ther-apy, 12, 3929-3235. [Google Scholar] [CrossRef]
|
|
[40]
|
Mefford, I.N. and Wade, E.U. (2009) Proton Pump Inhibitors as a Treatment Method for Type II Diabetes. Medical Hypotheses, 73, 29-32. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Suarez-Pinzon, W.L., Cembrowski, G.S. and Rabinovitch, A. (2009) Combination Therapy with A Dipeptidyl Peptidase-4 Inhibitor and A Proton Pump Inhibitor Restores Normogly-caemia in Non-Obese Diabetic Mice. Diabetologia, 52, 1680-1682. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Crouch, M.A., Mefford, I.N. and Wade, E.U. (2012) Proton Pump Inhibitor Therapy Associated with Lower Glycosylated Hemoglobin Levels in Type 2 Diabetes. Journal of the American Board of Family Medicine, 25, 50-54. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Inci, F., Atmaca, M., Ozturk, M., et al. (2014) Pantoprazole May Improve Beta Cell Function and Diabetes Mellitus. Journal of Endocrinological Investigation, 37, 449-454. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Singh, P.K., Hota, D., Dutta, P., et al. (2012) Pantoprazole Im-proves Glycemic Control in Type 2 Diabetes: A Randomized, Double-Blind, Placebocontrolled Trial. Journal of Clinical Endocrinology & Metabolism, 97, E2105-E2108. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Lin, H.-C., Hsiao, Y.-T., Lin, H.-L., et al. (2016) The Use of Proton Pump Inhibitors Decreases the Risk of Diabetes Mellitus in Patients with Upper Gastrointestinal Disease: A Popula-tion-Based Retrospective Cohort Study. Medicine, 95, E4195. [Google Scholar] [CrossRef]
|
|
[46]
|
Suarez-Pinzon, W.L., Lakey, J.R. and Rabinovitch, A. (2008) Combination Therapy with Glucagon-Like Peptide-1 and Gastrin Induces β-Cell Neogenesis from Pancreatic Duct Cells in Human Islets Transplanted in Immunodeficient Diabetic Mice. Cell Transplant, 17, 631-640. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Suarez-Pinzon, W.L. and Rabinovitch, A. (2011) Combination Therapy with A Dipeptidyl Peptidase-4 Inhibitor and A Proton Pump Inhibitor Induces β-Cell Neogenesis from Adult Human Pancreatic Duct Cells Implanted in Immunodeficient Mice. Cell Transplant, 20, 1343-1349. [Google Scholar] [CrossRef]
|
|
[48]
|
Abbasi, A., Corpeleijn, E., Postmus, D., et al. (2010) Plasma Procalcitonin Is Associated with Obesity, Insulin Resistance, and the Metabolic Syndrome. Journal of Clinical Endocri-nology & Metabolism, 95, E26-E31. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Hjuler, S.T., Gydesen, S., Andreassen, K.V., Karsdal, M.A. and Hen-riksen, K. (2017) The Dual Amylin- and Calcitonin-Receptor Agonist KBP-042 Works as Adjunct to Metformin on Fasting Hyperglycemia and HbA1c in a Rat Model of Type 2 Diabetes. Journal of Pharmacology and Experimental Therapeutics, 362, 24-30. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Andreassen, K.V., Michael Feigh, M., Hjuler, S.T., Gydesen, S., Henriksen, J.E., Beck-Nielsen, H., et al. (2014) A Novel Oral Dual Amylin and Calcitonin Receptor Agonist (KBP-042) Exerts Anti-Obesity and Antidiabetic Effects in Rats. American Journal of Physiology - Endocrinology and Metabolism, 307, E24-E33. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Binkley, N., Bolognese, M., Sidorowicz-Bialynicka, A., et al. (2012) A Phase 3 Trial of the Efficacy and Safety of Oral Recombinant Calcitonin: The Oral Calcitonin in Postmenopau-sal Osteoporosis (ORACAL) Trial. Journal of Bone and Mineral Research, 27, 1821-1829. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Zhou, H. and Seibel, M.J. (2017) Bone: Osteoblasts and Global Energy Metabolism—Beyond Osteocalcin. Nature Reviews Rheumatology, 13, 261-262. [Google Scholar] [CrossRef] [PubMed]
|